27-Mar-2024
No headlines found.
Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024
Globe Newswire (Tue, 5-Mar 7:00 AM ET)
Agios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024
Globe Newswire (Thu, 22-Feb 7:00 AM ET)
Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
Globe Newswire (Thu, 15-Feb 7:00 AM ET)
Globe Newswire (Fri, 2-Feb 7:00 AM ET)
Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio
Globe Newswire (Mon, 8-Jan 7:00 AM ET)
Globe Newswire (Wed, 3-Jan 6:30 AM ET)
Agios to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024
Globe Newswire (Tue, 2-Jan 7:00 AM ET)
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.
Agios Pharmaceuticals trades on the NASDAQ stock market under the symbol AGIO.
As of March 27, 2024, AGIO stock price climbed to $29.12 with 638,120 million shares trading.
AGIO has a beta of 1.64, meaning it tends to be more sensitive to market movements. AGIO has a correlation of 0.21 to the broad based SPY ETF.
AGIO has a market cap of $1.64 billion. This is considered a Small Cap stock.
Last quarter Agios Pharmaceuticals reported $7 million in Revenue and -$1.72 earnings per share. This fell short of revenue expectation by $-837,000 and missed earnings estimates by -$.07.
In the last 3 years, AGIO stock traded as high as $62.16 and as low as $16.75.
The top ETF exchange traded funds that AGIO belongs to (by Net Assets): VTI, XBI, VB, IWM, VXF.
AGIO has underperformed the market in the last year with a price return of +30.9% while the SPY ETF gained +33.6%. However, in the short term, AGIO had mixed performance relative to the market. It has outperformed in the last 3 months, returning +27.6% vs +10.1% return in SPY. But in the last 2 weeks, AGIO shares have been beat by the market, returning -2.9% compared to an SPY return of +1.7%.
AGIO support price is $28.31 and resistance is $29.81 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AGIO stock will trade within this expected range on the day.